CureLab Veterinary的ElenaVet™基因疗法在宠物狗骨关节炎研究中取得90%的成功率-动脉网

CureLab Veterinary's ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study

CISION 等信源发布 2025-06-14 02:54



可切换为仅中文







Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects

兽医学前沿论文报道，每周注射p62质粒可快速显著缓解疼痛，且无明显副作用。

BOSTON

波士顿

，

June 13, 2025

2025年6月13日

/PRNewswire/ --

CureLab Veterinary Inc.

CureLab兽医公司

, a pioneer in developing innovative veterinary therapeutics to combat cancer and inflammatory diseases in pets, announced publication of a peer-reviewed pilot study demonstrating that

，一家致力于开发创新兽医药物以对抗宠物癌症和炎症性疾病的先锋公司，宣布了一项经同行评审的初步研究结果发表，该研究表明

ElenaVet

埃莱娜兽医

™, the company's investigational p62-plasmid gene therapy, markedly reduced chronic osteoarthritis (OA) pain in companion dogs while exhibiting an excellent safety profile. The article, titled

™，该公司研发的p62质粒基因疗法，显著减轻了伴生犬的慢性骨关节炎（OA）疼痛，同时表现出极佳的安全性。文章标题为

'Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study,'

‘表达p62的质粒在治疗犬骨关节炎疼痛中的疗效：一项初步研究，’

appears in

出现在

Frontiers in Veterinary Science

兽医学前沿

(

DOI 10.3389/fvets.2025.1519881

数字对象标识符 10.3389/fvets.2025.1519881

）。

继续阅读

Frontiers in Veterinary Science (June 2025) features CureLab Veterinary’s peer-reviewed pilot study showing 90 % treatment-success with ElenaVet™ p62-plasmid gene therapy for canine osteoarthritis (DOI 10.3389/fvets.2025.1519881)

《兽医学前沿》（2025年6月）刊登了CureLab Veterinary的同行评审试点研究，显示ElenaVet™ p62质粒基因疗法在治疗犬骨关节炎方面的成功率达到90%（DOI 10.3389/fvets.2025.1519881）。

Key findings

主要发现

17 client-owned dogs with radiographically confirmed OA received 1 mg intramuscular ElenaVet™ once a week for 10 weeks.

17只患有放射学确诊骨关节炎的客户宠物狗每周接受一次1毫克的ElenaVet™肌肉注射，持续10周。

Pain Severity Score (PSS) fell from 5.25 → 3.25 and Pain Interference Score (PIS) from 7.0 → 3.27 on the Canine Brief Pain Inventory (CBPI).

在犬类简要疼痛量表（CBPI）中，疼痛严重程度评分（PSS）从5.25降至3.25，疼痛干扰评分（PIS）从7.0降至3.27。

90% of dogs met the study's pre-defined 'treatment success' criteria (≥1-point PSS drop and ≥2-point PIS drop). Quality-of-life ratings of 'good/excellent' rose from 1 to 12 dogs.

90%的狗达到了研究预设的“治疗成功”标准（PSS下降≥1分且PIS下降≥2分）。生活质量评级为“良好/优秀”的狗从1只增加到12只。

First owner-noticed improvements occurred within 2–4 weeks; scores plateaued by week 6.

主人首先注意到的改善发生在2至4周内；到第6周时，评分趋于平稳。

No significant adverse events—no vomiting, diarrhea, seizures, or lab abnormalities—were reported during treatment.

治疗期间未报告严重不良事件，无呕吐、腹泻、癫痫发作或实验室指标异常。

Executive & scientific commentary

执行与科学评论

'ElenaVet™ has now shown—in a rigorous, peer-reviewed setting—that a weekly gene-based therapy can deliver meaningful, durable pain relief without the organ-toxicity risks of long-term NSAID use,' said

“ElenaVet™ 现已在一项严格的同行评审环境中表明，一种每周一次的基于基因的疗法可以提供显著且持久的疼痛缓解，同时没有长期使用非甾体抗炎药（NSAID）带来的器官毒性风险，”

Robert Devlin

罗伯特·德夫林

, general manager of CureLab Veterinary. 'These results put us on a clear path toward larger, controlled trials and eventual U.S. approval.'

CureLab Veterinary总经理表示：“这些结果使我们朝着更大规模、受控试验和最终的美国批准迈出了明确的一步。”

'The p62 plasmid dampens multiple inflammatory pathways simultaneously,' added

“p62质粒同时抑制多种炎症通路，”他补充道。

Vladimir Gabai

弗拉基米尔·加拜

, PhD, chief science officer and lead author of the study. 'Because we encode p62 in a simple plasmid, we can administer a low-dose injection that teaches muscle cells to make the dog's own anti-inflammatory agent—no complex biologic manufacturing or cold chain required.'

博士，首席科学官兼该研究的首席作者。“因为我们是在一个简单的质粒中编码p62，所以我们可以注射低剂量，教会肌肉细胞生成狗自身产生的抗炎因子——不需要复杂的生物制造或冷链。”

Addressing a widespread unmet need

满足广泛的未满足需求

Osteoarthritis affects an estimated one in five adult dogs; chronic use of standard NSAIDs can raise blood pressure, cause gastric ulcers and, in some cases, damage kidneys or liver. ElenaVet™ aims to offer a safer, compliance-friendly alternative—potentially as monthly or 'as-needed' injections, once dose-frequency optimization studies are complete..

骨关节炎影响着约五分之一的成年犬；长期使用标准的非甾体抗炎药（NSAIDs）可能会升高血压、导致胃溃疡，并在某些情况下损害肾脏或肝脏。ElenaVet™ 旨在提供一种更安全且易于依从的替代方案——一旦剂量频率优化研究完成，可能以每月一次或“按需”注射的形式使用。

Next steps

下一步

CureLab Veterinary has initiated discussions with the USDA Center for Veterinary Biologics (CVB) to finalize pivotal study protocols assessing dose range, durability of effect and long-term safety. With adequate funding, the company anticipates submitting a licensing application within 2–3 years.

CureLab Veterinary 已开始与美国农业部兽医生物制品中心 (CVB) 展开讨论，以最终确定评估剂量范围、效果持久性和长期安全性的关键研究方案。在资金充足的情况下，该公司预计将在 2 至 3 年内提交许可申请。

About ElenaVet™

关于ElenaVet™

ElenaVet™ is a circular DNA plasmid encoding the SQSTM1/p62 protein, delivered via intramuscular injection. The therapy is designed to up-regulate the body's own anti-inflammatory mediators, providing multimodal relief from chronic inflammatory conditions such as osteoarthritis.

ElenaVet™ 是一种编码 SQSTM1/p62 蛋白的环状 DNA 质粒，通过肌肉注射给药。该疗法旨在上调体内自身的抗炎介质，为骨关节炎等慢性炎症疾病提供多模式的缓解。

About CureLab Veterinary Inc.

关于CureLab兽医公司

CureLab Veterinary Inc. is a pioneering biopharmaceutical company dedicated to developing innovative cancer treatments for pets. The company's mission is to help pets live longer, healthier, and happier lives by providing them with access to the most advanced therapies available. CureLab Veterinary is committed to advancing the field of veterinary oncology through research, development, and collaboration with leading academic institutions and industry partners.

CureLab Veterinary Inc. 是一家致力于为宠物开发创新癌症治疗的先锋生物制药公司。公司的使命是通过提供最先进的治疗方案，帮助宠物活得更长久、更健康、更快乐。CureLab Veterinary 致力于通过研究、开发以及与领先的学术机构和行业伙伴合作，推动兽医肿瘤学领域的发展。

The company's intellectual property portfolio, developed over the last decade, includes patents granted in more than 25 countries. To learn more, visit .

公司在过去十年中开发的知识产权组合包括在 25 个国家授予的专利。欲了解更多信息，请访问。

curelabveterinary.com

治愈实验室兽医网

。

Investigational status / safe-harbor statement

研究状态/安全港声明

ElenaVet™ is an investigational therapy not yet approved for commercial use; safety and efficacy have not been established by U.S. regulatory authorities. This press release contains forward-looking statements subject to risks and uncertainties.

ElenaVet™ 是一种尚未获准用于商业使用的研究性疗法；其安全性和有效性尚未得到美国监管机构的证实。本新闻稿包含受风险和不确定性影响的前瞻性声明。

Media contact

媒体联系人

Tim Cox

蒂姆·考克斯

| ZingPR for CureLab Veterinary |

| ZingPR为CureLab兽医 |

tim@zingpr.com

SOURCE CureLab Veterinary

来源：CureLab兽医

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗